| 1 |
32988919 | Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. | 2020 Oct |
1 |
| 2 |
33005299 | Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report. | 2020 Sep 15 |
1 |
| 3 |
30624609 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. | 2019 Jul 1 |
1 |
| 4 |
29110152 | Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. | 2018 Feb |
1 |
| 5 |
29701763 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. | 2018 Oct 1 |
1 |
| 6 |
28478451 | Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. | 2017 |
1 |
| 7 |
26920887 | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. | 2016 Aug 1 |
1 |
| 8 |
27177864 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. | 2016 Aug |
1 |
| 9 |
25559818 | PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. | 2015 Apr 20 |
2 |
| 10 |
26181325 | Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. | 2015 |
4 |
| 11 |
26245675 | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. | 2015 Sep |
1 |
| 12 |
26281684 | [PI3K and mTOR pathway and molecular targeted agents]. | 2015 Aug |
1 |
| 13 |
24249715 | Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor. | 2014 Jan |
8 |
| 14 |
24590635 | Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. | 2014 Apr 1 |
1 |
| 15 |
25056500 | Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. | 2014 Jul 24 |
2 |
| 16 |
25195596 | Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. | 2014 Dec |
1 |
| 17 |
25199759 | PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. | 2014 Oct 10 |
1 |
| 18 |
23633485 | Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. | 2013 Jul 1 |
1 |
| 19 |
21499301 | Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. | 2011 Sep 29 |
3 |
| 20 |
21676217 | PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. | 2011 Jun 15 |
1 |
| 21 |
21293538 | Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. | 2010 Dec |
1 |
| 22 |
19844234 | Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. | 2009 Nov 17 |
1 |
| 23 |
19010894 | Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | 2008 Nov 15 |
5 |